Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial Assessing the Combination of Sulfasalazine With Standard of Care Induction Therapy in Newly Diagnosed Acute Myeloid Leukemias (AML) Patients 60 Years or Older- the SALMA Study

NCT05580861 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05580861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial Assessing the Combination of Sulfasalazine With Standard of Care Induction Therapy in Newly Diagnosed Acute Myeloid Leukemias (AML) Patients 60 Years or Older- the SALMA Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 17, 2023
Completion date
December 31, 2026
Enrollment
64 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia